Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.02.002 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.02.002 33705704!7945883!33705704     free     free     free       Cell+Host+Microbe 2021 ; 29 (3): 327-333 Nephropedia Template TP {{tp|p=33705704|t=2021. Virus vaccines: proteins prefer prolines |pdf=|usr=}}{{33705704}} gab.com Text Virus vaccines: proteins prefer prolines JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33705704 #FOAvip Most viral vaccines are based on inducing neutralizing antibodies (NAbs) against the virus envelope or spike glycoproteins. Many viral surface proteins exist as trimers that transition from a pre-fusion state when key NAb epitopes are exposed to a post-fusion form in which the potential for virus-cell fusion no longer exists. For optimal vaccine performance, these viral proteins are often engineered to enhance stability and presentation of these NAb epitopes. The method involves the structure-guided introduction of proline residues at key positions that maintain the trimer in the pre-fusion configuration. We review how this technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2. Twit Text FOAVip Virus vaccines: proteins prefer prolines ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33705704 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33705704 #FOAvip English Wikipedia <ref>{{Cite pmid|33705704}}</ref> Virus vaccines: proteins prefer prolines #MMPMID33705704 Sanders RW; Moore JP Cell Host Microbe 2021[Mar]; 29 (3): 327-333 PMID33705704show ga Most viral vaccines are based on inducing neutralizing antibodies (NAbs) against the virus envelope or spike glycoproteins. Many viral surface proteins exist as trimers that transition from a pre-fusion state when key NAb epitopes are exposed to a post-fusion form in which the potential for virus-cell fusion no longer exists. For optimal vaccine performance, these viral proteins are often engineered to enhance stability and presentation of these NAb epitopes. The method involves the structure-guided introduction of proline residues at key positions that maintain the trimer in the pre-fusion configuration. We review how this technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2. |Antibodies, Neutralizing/immunology[MESH] |COVID-19 Vaccines/chemistry/genetics/immunology[MESH] |Humans[MESH] |Models, Molecular[MESH] |Proline/*chemistry/genetics/*immunology[MESH] |Protein Engineering[MESH]Virus vaccines: proteins prefer prolines (epmc).pdf DeepDyve Pubget Overpricing